MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.

New analyses of ESTEEM trials evaluate safety, efficacy and tolerability of OTEZLA in patients with moderate to severe plaque psoriasis

Analysis of PALACE 52-week data assesses impact of OTEZLA on signs and symptoms of psoriatic arthritis

11 featured abstracts underscore growing body of evidence and depth of the OTEZLA clinical development program in plaque psoriasis and psoriatic arthritis

OTEZLA recently approved by the U.S. Food and Drug Administration for moderate to severe plaque psoriasis patients who are candidates for phototherapy or systemic therapy

BOUDRY, Switzerland --(BUSINESS WIRE)-- 07.10.2014 --

Celgene International Srl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that the latest research findings on OTEZLA (apremilast), the Companys oral, selective inhibitor of phosphodiesterase 4 (PDE4), in plaque psoriasis and psoriatic arthritis will be presented at the 23rd European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, October 8 12, 2014. In total, 11 abstracts (two oral presentations and nine e-Posters) will be presented at the meeting.

OTEZLA data to be presented include long-term (52-week) results from Celgenes pivotal trial, ESTEEM 2 and pooled analyses of safety and tolerability results from the ESTEEM 1 and 2 studies in patients with moderate to severe plaque psoriasis. Additional analyses will evaluate the effect of OTEZLA on pruritus (itching), difficult-to-treat areas such as nail and scalp, and palmoplantar (hand and feet) psoriasis, work productivity and improvements in health-related quality of life.

An analysis of long-term results from the PALACE clinical trial program evaluating OTEZLA in patients with active psoriatic arthritis will also be presented at the meeting. The analysis assesses the effect of OTEZLA treatment through 52 weeks on the signs and symptoms of psoriatic arthritis, including enthesitis (inflammation at sites where tendons or ligaments insert into bone) and dactylitis (inflammation of an entire finger or toe) in patients with pre-existing enthesitis or dactylitis.

During the Congress, Celgene will host a variety of programs focusing on the unmet needs for people living with psoriasis and psoriatic arthritis, including a symposium for healthcare professionals and programs for patient/professional advocacy organizations and media.

View original post here:

BUSINESS WIRE: Celgene to Present Long-Term Efficacy and Safety Data on Oral OTEZLA (apremilast) in Plaque Psoriasis ...